May 29, 2019
November 16, 2015
Lung cancer is the leading cause of death from cancer in the U.S. for both men and women. According to the American Cancer Society, each year more people die of lung cancer than of colon, breast, and prostate cancers combined. And because most lung cancers have already spread and are at an advanced stage when they are first found, treatment can be challenging.
Rarely is there much good news to share. In 2015, that changed.
Big breakthroughs in immunotherapy made 2015 a landmark year for lung cancer treatment, bringing new hope to millions of people throughout the world. Since 2015 there have been multiple advancements in immunotherapy. This is leading to even better outcomes for patients with all types of lung cancer, including small cell and non-small cell lung cancer. You've likely seen television commercials for some of the new immunotherapy drugs.
What Is Immunotherapy?
Immunotherapy is a new way to treat cancer by tapping into the unique powers of the immune systems to fight the disease. The FDA has approved four immunotherapy drugs, nivolumab (Opdivo®), pembrolizumab (Keytruda®), atezolizumab (Tecentriq), and durvalumab (Imfinzi) to treat lung cancer in various stages of disease. Immunotherapy has been shown to improve survival in patients with advanced lung cancer whether it is given with chemotherapy, alone, or after chemotherapy and radiation.
Clinical Trials Make Breakthroughs Possible
These exciting advancements could not have been possible without clinical trials. Thanks to those who participate in clinical trials research, people with cancer are living longer and with a better quality of life than ever before.
In Lancaster, the Ann B. Barshinger Cancer Institute offers opportunities for participation in numerous studies. Patients who take part in these studies receive either the best treatment currently known for their specific cancer, or new and possibly more effective therapy.
Click here to learn how you or someone you know might become involved.
Lung Cancer CT Screening
If you’re a current or former smoker and are concerned about your risk for developing lung cancer, a low-dose lung cancer CT screening may be right for you. An online assessment can help you find out if you’re eligible.